{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild+to+Moderate+Alzheimer%27s+Disease&page=7",
    "query": {
      "condition": "Mild to Moderate Alzheimer's Disease",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 199,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild+to+Moderate+Alzheimer%27s+Disease&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild+to+Moderate+Alzheimer%27s+Disease&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T17:09:32.031Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00100282",
      "title": "Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "PPI-1019 (APAN)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PRAECIS Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 125,
      "start_date": "2003-05",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2006-09-19",
      "last_synced_at": "2026-11-19T17:09:32.031Z",
      "location_count": 2,
      "location_summary": "Orange, California • Princeton, New Jersey",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00100282"
    },
    {
      "nct_id": "NCT03625622",
      "title": "Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild to Moderate Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "AR1001 10mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "AR1001 30mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AriBio Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "55 Years to 80 Years"
      },
      "enrollment_count": 210,
      "start_date": "2019-04-01",
      "completion_date": "2021-06-28",
      "has_results": true,
      "last_update_posted_date": "2026-11-19",
      "last_synced_at": "2026-11-19T17:09:32.031Z",
      "location_count": 21,
      "location_summary": "Banning, California • Sacramento, California • Santa Ana, California + 18 more",
      "locations": [
        {
          "city": "Banning",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03625622"
    },
    {
      "nct_id": "NCT00093951",
      "title": "SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "SGS742",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Saegis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 280,
      "start_date": "2004-04",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2009-12-11",
      "last_synced_at": "2026-11-19T17:09:32.031Z",
      "location_count": 59,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00093951"
    },
    {
      "nct_id": "NCT00676143",
      "title": "Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "bapineuzumab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "88 Years",
        "sex": "ALL",
        "summary": "50 Years to 88 Years"
      },
      "enrollment_count": 1100,
      "start_date": "2008-01",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2016-06-10",
      "last_synced_at": "2026-11-19T17:09:32.031Z",
      "location_count": 111,
      "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 54 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00676143"
    },
    {
      "nct_id": "NCT01122329",
      "title": "A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "caprylidene",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 17,
      "start_date": "2010-10",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2015-03-23",
      "last_synced_at": "2026-11-19T17:09:32.031Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01122329"
    },
    {
      "nct_id": "NCT00960531",
      "title": "A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "ACC-001+ QS21 (3mcg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACC-001 (10 mcg) + QS-21",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACC-001+QS-21 (30mcg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 160,
      "start_date": "2009-07",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2016-04-01",
      "last_synced_at": "2026-11-19T17:09:32.031Z",
      "location_count": 28,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00960531"
    },
    {
      "nct_id": "NCT00818662",
      "title": "A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer´s Disease"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo solution: Human Albumin 0.25% - 4 mL/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo solution: Human Albumin 0.25% - 2 mL/kg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "50 Years to 89 Years"
      },
      "enrollment_count": 390,
      "start_date": "2008-12-19",
      "completion_date": "2012-12-10",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-11-19T17:09:32.031Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00818662"
    },
    {
      "nct_id": "NCT03522129",
      "title": "Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "CT1812",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cognition Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 3,
      "start_date": "2018-05-30",
      "completion_date": "2019-02-06",
      "has_results": false,
      "last_update_posted_date": "2022-01-12",
      "last_synced_at": "2026-11-19T17:09:32.031Z",
      "location_count": 2,
      "location_summary": "New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03522129"
    },
    {
      "nct_id": "NCT00381238",
      "title": "Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "rosiglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 33,
      "start_date": "2006-06-20",
      "completion_date": "2009-02-03",
      "has_results": true,
      "last_update_posted_date": "2017-05-23",
      "last_synced_at": "2026-11-19T17:09:32.031Z",
      "location_count": 6,
      "location_summary": "Litchfield Park, Arizona • Phoenix, Arizona • Sun City, Arizona + 3 more",
      "locations": [
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Belmont",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00381238"
    },
    {
      "nct_id": "NCT00988598",
      "title": "A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "PF-04447943",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 15,
      "start_date": "2009-10-26",
      "completion_date": "2010-07-05",
      "has_results": true,
      "last_update_posted_date": "2020-11-19",
      "last_synced_at": "2026-11-19T17:09:32.031Z",
      "location_count": 3,
      "location_summary": "Glendale, California • Gainesville, Florida • Hallandale, Florida",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00988598"
    }
  ]
}